




RealRate

PHARMACEUTICAL 2022

Lumos Pharma INC
Rank 119 of 471

lumos
PHARMA



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lumos Pharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lumos Pharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 107% points. The greatest weakness of Lumos Pharma INC is the variable Other Revenues, reducing the Economic Capital Ratio by 10% points.

The company's Economic Capital Ratio, given in the ranking table, is 364%, being 89% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	99,677
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,130
Liabilities, Non-Current	6,205
Other Assets	556
Other Compr. Net Income	0
Other Expenses	-636
Other Liabilities	0
Other Net Income	281
Other Revenues	230
Property and Equipment	79
Research and Development	16,246
Selling, General and Administrative Expense	15,331

Output Variable	Value in 1000 USD
Assets	100,312
Liabilities	11,335
Expenses	30,941
Revenues	230
Stockholders Equity	88,977
Net Income	-30,430
Comprehensive Net Income	-30,430
BaseVar	71,550
ECR before LimitedLiability	293%
Economic Capital Ratio	364%